EP 1430894 A1 20040623 - LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE
Title (en)
LYMPHOCYTIC ACTIVATION INHIBITOR AND REMEDIAL AGENT FOR AUTOIMMUNE DISEASE
Title (de)
LYMPHOZYTEN-AKTIVIERUNGSHEMMER UND MITTEL ZUR BEHANDLUNG VON AUTOIMMUNKRANKHEITEN
Title (fr)
INHIBITEUR D'ACTIVATION LYMPHOCYTAIRE ET REMEDE POUR MALADIE AUTO-IMMUNE
Publication
Application
Priority
- JP 0209030 W 20020905
- JP 2001269480 A 20010905
Abstract (en)
A lymphocyte activation inhibitor and a therapeutic agent for an autoimmune disease, each comprising, as an active ingredient, a sulfonamide derivative or sulfonic acid ester derivative represented by the following general formula (I): <CHEM> wherein the ring A represents a monocyclic or bicyclic aromatic ring which may be substituted, the ring B represents a 6-membered unsaturated hydrocarbon ring or a 6-membered unsaturated heterocyclic ring containing one nitrogen atom as a heteroatom, each of which may be substituted, the ring C represents a 5-membered heterocyclic ring containing one or two nitrogen atoms, which may be substituted, W represents a single bond or -CH=CH-, X represents -N(R<1>)- or an oxygen atom, Y represents a carbon atom or a nitrogen atom, Z represents -N(R<2>)- or a nitrogen atom, and R<1> and R<2> may be identical or different and each represents a hydrogen atom or a lower alkyl group, or a pharmacologically acceptable salt thereof, or a hydrate thereof.
IPC 1-7
A61K 31/404; A61K 31/416; A61K 31/4178; A61K 31/427; A61K 31/437; A61K 31/4439; A61K 45/00; A61P 1/00; A61P 1/02; A61P 3/10; A61P 5/50; A61P 19/02; A61P 19/04; A61P 25/00; A61P 27/02
IPC 8 full level
A61K 31/404 (2006.01); A61K 31/416 (2006.01); A61K 31/4178 (2006.01); A61K 31/427 (2006.01); A61K 31/437 (2006.01); A61K 31/4439 (2006.01); A61K 45/06 (2006.01); A61P 1/00 (2006.01); A61P 1/02 (2006.01); A61P 3/10 (2006.01); A61P 5/50 (2006.01); A61P 19/02 (2006.01); A61P 19/04 (2006.01); A61P 25/00 (2006.01); A61P 27/02 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); A61P 37/02 (2006.01)
CPC (source: EP US)
A61K 31/404 (2013.01 - EP US); A61K 31/416 (2013.01 - EP US); A61K 31/4178 (2013.01 - EP US); A61K 31/427 (2013.01 - EP US); A61K 31/437 (2013.01 - EP US); A61K 31/4439 (2013.01 - EP US); A61K 45/06 (2013.01 - EP US); A61P 1/00 (2017.12 - EP); A61P 1/02 (2017.12 - EP); A61P 1/04 (2017.12 - EP); A61P 3/10 (2017.12 - EP); A61P 5/50 (2017.12 - EP); A61P 19/02 (2017.12 - EP); A61P 19/04 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 29/00 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61P 37/02 (2017.12 - EP); A61P 37/06 (2017.12 - EP); A61P 43/00 (2017.12 - EP)
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
DOCDB simple family (publication)
EP 1430894 A1 20040623; EP 1430894 A4 20071212; CN 1551766 A 20041201; JP WO2003022271 A1 20041224; TW 589181 B 20040601; US 2004235866 A1 20041125; WO 03022271 A1 20030320
DOCDB simple family (application)
EP 02798032 A 20020905; CN 02817484 A 20020905; JP 0209030 W 20020905; JP 2003526400 A 20020905; TW 91120346 A 20020905; US 48865404 A 20040304